8-K: Crinetics Pharmaceuticals Announces Positive Initial Results for Atumelnant and Paltusotine at ENDO 2024

Crinetics Pharmaceuticals shared promising initial data for atumelnant in congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome, and presented new data supporting paltusotine as a potential first-choice treatment for acromegaly.

Summary

• Crinetics Pharmaceuticals announced positive initial findings for atumelnant, a novel oral ACTH receptor antagonist, in two open-label studies for congenital adrenal hyperplasia (CAH) and ACTH-dependent Cushing's syndrome (ADCS).
• In the CAH study, 100% of participants (n=6) maintained androstenedione (A4) levels below the upper limit of normal on 80 mg of atumelnant.
• CAH participants achieved over 90% reduction in A4 and 97% reduction in 17-OHP with 80 mg of atumelnant, starting at two weeks and sustained through 12 weeks.
• In the ADCS trial, 100% of participants (n=5) normalized 24-hour urinary free cortisol levels with 80 mg of atumelnant.
• Crinetics also presented new data for paltusotine in acromegaly, including results from the Phase 3 PATHFNDR-2 trial, a new analysis of patient-reported outcomes from the Phase 3 PATHFNDR-1 trial, and long-term data from the ACROBAT Advance extension study.
• The PATHFNDR-2 trial showed that 56% of participants on paltusotine achieved IGF-1 levels at or below 1.0 times the upper limit of normal, compared to 5% on placebo.
• A new analysis of the PATHFNDR-1 trial showed that paltusotine reduced the frequency of acromegaly breakthrough symptom exacerbations compared to prior standard-of-care injections.
• Long-term data from the ACROBAT Advance study demonstrated durable safety, IGF-1, and symptom control at up to 42 months of paltusotine treatment.
• Crinetics plans to submit a New Drug Application (NDA) for paltusotine in the second half of 2024.

Sentiment

Score: 9

Explanation: The document presents highly positive clinical trial results for both atumelnant and paltusotine, with strong efficacy and safety data. The company is moving towards regulatory submissions, indicating a high likelihood of future success.

Positives

• Atumelnant demonstrated rapid and profound reductions in key adrenal steroids in both CAH and ADCS patients.
• Atumelnant was generally well-tolerated with mild to moderate adverse events.
• Paltusotine showed rapid and sustained IGF-1 responses in acromegaly patients.
• Paltusotine was well-tolerated with no serious adverse events reported in the PATHFNDR-2 trial.
• Paltusotine may offer less day-to-day symptom variability compared to standard-of-care injections for acromegaly.
• Two female participants in the CAH study resumed regular menstrual cycles on atumelnant after not menstruating for over two years.

Negatives

• Some participants in the atumelnant studies experienced mild to moderate adverse events such as fatigue, headache, and upper respiratory tract infection.
• Predefined biochemical adrenal insufficiency was observed in all participants treated with atumelnant, requiring hydrocortisone replacement.
• Two participants with pre-existing steatosis had small increases in ALT while on atumelnant.
• The most common adverse events in paltusotine-treated participants included diarrhea, headache, arthralgia, and abdominal pain.

Risks

• The reported initial or topline data may change following a more comprehensive review of the data.
• The FDA and other regulatory authorities may not agree with the company's interpretation of the results.
• Unexpected adverse side effects or inadequate efficacy of the product candidates may limit their development, regulatory approval, and/or commercialization.
• Clinical studies may not proceed as expected.
• The timing and outcome of research, development, and regulatory review are uncertain.

Future Outlook

Crinetics plans to complete the Phase 2 study in CAH and the Phase 1b/2a study in ADCS, report topline data in the second half of 2024, design Phase 3 trials for CAH, and submit an NDA for paltusotine in the second half of 2024. They also plan to advance the development of atumelnant in ADCS.

Management Comments

• Scott Struthers, Ph.D., CEO of Crinetics, stated that the data show an impressive ability of atumelnant to reduce key disease drivers to healthy levels.
• Scott Struthers, Ph.D., CEO of Crinetics, noted that the paltusotine data demonstrates its rapid, durable effect on both biochemical and symptom control.
• Alan Krasner, M.D., chief endocrinologist at Crinetics, stated that paltusotine may be associated with less day-to-day symptom variability compared to injections.

Industry Context

The announcement highlights Crinetics' progress in developing novel treatments for endocrine disorders, positioning them as a key player in the pharmaceutical industry focused on these conditions. The positive results for both atumelnant and paltusotine could potentially disrupt the current treatment paradigms for CAH, ADCS, and acromegaly.

Comparison to Industry Standards

• Current treatments for CAH often involve high doses of glucocorticoids, which can have significant side effects. Atumelnant's ability to directly inhibit ACTH at its receptor offers a novel approach.
• Existing treatments for ADCS have limitations, including unpredictable efficacy and adverse events. Atumelnant's ability to normalize cortisol levels in all participants is a significant improvement.
• Current acromegaly treatments often involve painful monthly injections. Paltusotine's oral, once-daily administration offers a more convenient alternative.
• The PATHFNDR-2 trial results for paltusotine, with 56% of patients achieving target IGF-1 levels, compare favorably to the efficacy rates of existing injectable somatostatin analogs, which typically range from 50-80%.
• The patient-reported outcome data from PATHFNDR-1, showing reduced symptom exacerbations with paltusotine, addresses a key unmet need in acromegaly management.

Stakeholder Impact

• Shareholders: The positive clinical trial results are likely to positively impact the company's stock price.
• Patients: The development of atumelnant and paltusotine offers new treatment options with potentially improved efficacy and convenience.
• Employees: The progress in clinical trials may boost employee morale and job security.
• Customers: The company's focus on developing novel therapeutics for endocrine diseases may lead to new partnerships and collaborations.
• Suppliers: The company's growth may lead to increased demand for supplies and services.

Next Steps

• Complete the Phase 2 study in CAH (TouCAHn) and report top-line data in 2H 2024.
• Complete the Phase 1b/2a study in ADCS and report additional data in 2H 2024.
• Design Phase 3 trial for CAH and align with regulators.
• Design ADCS later stage development plan and align with regulators.
• Submit a New Drug Application (NDA) for paltusotine in the second half of 2024.

Key Dates

Keywords

atumelnant, paltusotine, acromegaly, congenital adrenal hyperplasia, Cushing's syndrome, ACTH antagonist, somatostatin receptor agonist, endocrine diseases, clinical trials, hormone therapy